Applying small RNA molecules to the directed treatment of human diseases: Realizing the potential

Expert Opinion on Therapeutic Targets

Volumn 12, Issue 1, 2008, Pages 115-127

  Pappas, Todd C ^a   Bader, Andreas G ^a   Andruss, Bernard F ^a   Brown, David ^a   Ford, Lance P ^b  

^a ASURAGEN INC   (United States)

^b BIOO Scientific   (United States)

Author keywords

Delivery; MicroRNA; RNA drugs; Small interfering RNA; Therapeutics

Indexed keywords

AGN 211745; AKLI 5; ALN RSV 01; AMPHOTERICIN B LIPID COMPLEX; ANTIBODY; APOLIPOPROTEIN B; ATELOCOLLAGEN; BEVASIRANIB; CASPASE 8; CYCLODEXTRIN; DAUNORUBICIN; DNA; DOXORUBICIN; HYBRID PROTEIN; IMMUNOLIPOSOME; MICRORNA; PCS 01; RNA DERIVATIVE; RTP 108I; SIRNA 027; SIRNA 034; SMALL INTERFERING RNA; TT 033; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANTISENSE THERAPY; ASTHMA; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TOLERABILITY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE SILENCING; GENE THERAPY; HUMAN; HUNTINGTON CHOREA; HYDRODYNAMICS BASED TRANSFECTION; HYPERCHOLESTEROLEMIA; INFLUENZA; KIDNEY DISEASE; LIPOSOMAL GENE DELIVERY SYSTEM; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RNA INTERFERENCE; SEQUENCE HOMOLOGY; SEVERE ACUTE RESPIRATORY SYNDROME; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSLATION REGULATION; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENE SILENCING; GENE TARGETING; HUMANS; MICRORNAS; RNA, SMALL INTERFERING;

EID: 39049156763     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.12.1.115     Document Type: Review

References (115)

1. IBC Life Sciences. Oligonucleotide and Peptide® Technology and Product Development Proven Strategies for Successful Drug and Diagnostic Development. 2007 20-23 May, Las Vegas, NV, USA
2. Stein CA, Cohen JS. Oligodeoxynucleotides as inhibitors of gene expression: a review. Cancer Res 1988;48(10):2659-68
3. Aartsma-Rus A, Van Ommen G-JB. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 2007; [Epub ahead of print]
4. Cheng JQ Ruggeri B, Klein WM, et al. Amplification of AKT2 in human pancreatic cancer cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 1996;93(8):3636-41
5. Singh M, Savitz SI, Hoque R, et al. Cell-specific caspase expression by different neuronal phenotypes in transient retinal ischemia. J Neurochem 2001;77(2):466-75
6. 3 expression and integrin-mediated signaling in glioma cells by adenovirus-mediated transfer of antisense urokinase-type plasminogen activator receptor (uPAR) and sense p16 genes. J Biol Chem 2001;276(50):47171-7
7. Calderone A, Jover T, Noh K-M, et al. Ischemic insults derepress the gene silencer REST in neurons destined to die. J Neurosci 2003;23(6):2112-21
8. Renshaw J, Orr RM, Walton MI, et al. Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival. Mol Cancer Ther 2004;3(11):1467-84
9. London CA, Sekhon HS, Arora V, et al. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Ther 2003;10(11):823-32
10. http://www.genta.com/Products-genasense.html
11. Que-Gewirth NS, Sullenger BA. Gene therapy progress and prospects: RNA aptamers. Gene Ther 2007;14(4):283-91
12. Ulrich H, Trujillo CA, Nery AA, et al. DNA and RNA aptamers: from tools for basic research towards therapeutic applications. Comb Chem High Throughput Screen 2006;9(8):619-32
13. Brody EN, Gold L. Aptamers as therapeutic and diagnostic agents. J Biotechnol 2000;74(1):5-13
14. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005;40(3):352-68
15. Vinores SA. Technology evaluation: pegaptanib, Eyetech/Pfizer. Curr Opin Mol Ther 2003;5(6):673-9
16. Bell C, Lynam E, Landfair DJ, Janjic N, Wiles ME. Oligonucleotide NX1838 inhibits VEGF 165-mediated cellular responses in vitro. In Vitro Cell Dev Biol Anim 1999;35(9):533-42
17. Dikmen ZG, Gellert GC, Jackson S, et al. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res 2005;65(17):7866-73
18. Djojosubroto MW, Chin AC, Go N, et al. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology 2005;42(5):1127-36
19. Dykxhoorn DM, Novina CD, Sharp PA. Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 2003;4(6):457-67
20. Shivdasani RA. MicroRNAs: regulators of gene expression and cell differentiation. Blood 2006;108(12):3646-53
21. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006;6(4):259-69
22. Jackson AL, Bartz SR, Schelter J, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003;21(6):635-7
23. Schwarz DS, Ding H, Kennington L, et al. Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet 2006;2(9):E140
24. Jackson AL, Burchard J, Leake D, et al. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 2006;12(7):1197-205
25. Birmingham A, Anderson EM, Reynolds A, et al. 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 2006;3(3):199-204
26. Miller VM, Xia H, Marrs GL, et al. Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci USA 2003;100(12):7195-200
27. Miller VM, Gouvion CM, Davidson BL, Paulson HL. Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles. Nucleic Acids Res 2004;32(2):661-8
28. Xia X, Zhou H, Huang Y, Xu Z. Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo. Neurobiol Dis 2006;23(3):578-86
29. www.ambion.com/techlib/misc/siRNA_finder.html
30. Reynolds A, Leake D, Boese Q, et al. Rational siRNA design for RNA interference. Nat Biotechnol 2004;22(3):326-30
31. Hutvagner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex. Science 2002;297(5589):2056-60
32. Aleman LM, Doench J, Sharp PA. Comparison of siRNA-induced off-target RNA and protein effects. RNA 2007;13(3):385-95
33. Layzer JM, McCaffrey AP, Tanner AK, et al. In vivo activity of nuclease-resistant siRNAs. RNA 2004;10(5):766-71
34. Csauderna F, Fechtner M, Dames S, et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 2003;31(11):2705-16
35. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin- 14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993;75(5):855-62
36. Grishok A, Pasquinelli AE, Conte D, et al. Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing. Cell 2001;106(1):23-34
37. Hamilton A, Voinner O, Chappell L, Baulcombe D. Two classes of short interfering RNA in RNA silencing. EMBO J 2002;21(17):4671-9
38. Yekta S, Shih IH, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. Science 2004;304(5670):594-6
39. Lee RC, Feinbaum RL, Ambros V. The C. elegant heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75(5):843-54
40. Olsen PH, Ambros V. The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation. Dev Biol 1999;216(2):671-80
41. Pillai RS, Artus CG, Filipowicz W. Tethering of human Ago proteins to mRNA mimics the miRNA-mediated repression of protein synthesis. RNA 2004;10(10):1518-25
42. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004;116(2):281
43. Liu J, Valencia-Sanchez MA, Hannon GJ, Parker R. MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nat Cell Biol 2005;7(7):719-23
44. Wu L, Fan J, Belasco JG. MicroRNAs direct rapid deadenylation of mRNA. Proc Natl Acad Sci USA 2006;103(11):4034-9
45. Mathonnet G, Fabian MR, Svitkin YV, et al. MicroRNA inhibition of translation initiation in vitro by targeting the cap-binding complex eIF4F. Science 2007;317(5845):1764-7
46. Chen J, Li WX, Xie D, Ping JR, Ding SW. Viral virulence protein suppresses RNA silencing-mediated defense but upregulates the role of microrna in host gene expression. Plant Cell 2004;16(5):1302-13
47. Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM. bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell 2003;113(1):25-36
48. Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 2005;33(4):1290-7
49. Johnson CD, Esquela-Kerscher A, Stefani G, et al. The let-7 MicroRNA represses cell proliferation pathways in human cells. Cancer Res 2007;67(16):7713-22
50. Meng F, Henson R, Lang M, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006;130(7):2113-29
51. Bentwich I. Prediction and validation of microRNAs and their targets. FEBS Lett 2005;579(26):5904-10
52. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120(1):15
53. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9(3):189-98
54. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006;103(7):2257-61
55. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6(11):857-66
56. Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353(17):1793-801
57. Calm GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA 2004;101(32):11755-60
58. Cummins JM, He Y, Leary RJ, et al. The colorectal microRNAome. Proc Natl Acad Sci USA 2006;103(10):3687-92
59. Lu C, Tej SS, Luo S, et al. Elucidation of the small RNA component of the transcriptome. Science 2005;309(5740): 1567-9
60. Metzler M, Wilda M, Busch K, Viehmann S, Borkhardt A. High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer 2004;39(2):167-9
61. Michael MZ, Sm OC, Van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003;1(12):882-91
62. Si ML, Zhu S, Wu H, et al. miR-21-mediated tumor growth. Oncogene 2006;26(19):2799-803
63. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435(7043):828-33
64. Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpresaed in human lung cancers and enhances cell proliferation. Cancer Res 2005;65(21):9628-32
65. Dews M, Homayouni A, Yu D, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet 2006;38(9):1060-5
66. Costinean S, Zanesi N, Pekarsky Y, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E{micro}-miR155 transgenic mice. Proc Natl Acad Sci USA 2006;103:7024-9
67. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005;65(14):6029-33
68. Johnson SM, Grosshans H, Shingara J, et al. RAS Is Regulated by the let-7 MicroRNA Family. Cell 2005;120(5):635
69. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005;102(39):13944-9
70. Carmell MA, Xuan Z, Zhang MQ, Hannon GJ. The Argonaute family: tentacles that reach into RNAi, developmental control, stem cell maintenance, and tumorigenesis. Genes Dev 2002;16(21):2733-42
71. Karube Y, Tanaka H, Osada H, et al. Reduced capression of dicer associated with poor prognosis in lung cancer patients. Cancer Sci 2005;96(2):111-5
72. Chiosea S, Jelezcova E, Chandran U, et al. Up-regulation of dicer, a component of the MicroRNA machinery in prostate adenocarcinoma. Am J Pathol 2006;169(5):1812-20
73. Voorhoeve PM, Le Sage C, Schrier M, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006;124(6):1169-81
74. Mccaffrey AP, Meuse L, Pham TT, et al. RNA interference in adult mice. Nature 2002;418(6893):38-9
75. Lewis DL, Hagstrom JE, Loomis AG, Wolff JA, Herweijer H. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet 2002;32(1):107-8
76. Hamar P, Song E, Kokeny G, et al. Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. Proc Natl Acad Sci USA 2004;101(41):14883-8
77. Song E, Lee SK, Wang J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003;9(3):347-51
78. Zender L, Hutker S, Liedtke C, et al. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci USA 2003;100(13):7797-802
79. Sorensen DR, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 2003;327(4):761-6
80. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004;432(7014):73
81. Li BJ, Tang Q, Cheng D, et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med 2005;11(9):944-51
82. Dorn G, Patel S, Wotherspoon G, et al. siRNA relieves chronic neuropathic pain. Nucleic Acids Res 2004;32(5):E49
83. Lomas-Neira JL, Chung CS, Wesche DE, Pen M, Ayala A. In vivo gene silencing (with siRNA) of pulmonary expression of MIP-2 versus KC results in divergent effects on hemorrhage-induced, neutrophil-mediated septic acute lung injury. J Leukoc Biol 2005;77(6):846-53
84. Bangham AD. A correlation between surface charge and coagulant action of phospholipids. Nature 1961;192:1197-8
85. Juliano RL, Lopez-Berestein G, Hopfer R, et al. Selective toxicity and enhanced therapeutic index of liposomal polyene antibiotics in systemic fungal infections. Ann NY Acad Sci 1985;446:390-402
86. Rahman A, Fumagalli A, Goodman A, Schein PS. Potential of liposomes to ameliorate anthracycline-induced cardiotoxicity. Semin Oncol 1984;11(4 Suppl 3):45-55
87. Fichtner I, Arndt D, Elbe B, Reszka R. Cardiotoxicity of free and liposomally encapsulated rubomycin (daunorubicin) in mice. Oncology 1984;41(5):363-9
88. Forssen EA, Tokes ZA. Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity. Proc Natl Acad Sci USA 1981;78(3):1873-7
89. Leung RK, Whittaker PA. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol Ther 2005;107(2):222-39
90. Maurer N, Fenske DB, Cullis PR. Developments in liposomal drug delivery systems. Expert Opin Biol Ther 2001;1(6):923-47
91. Dass CR Liposame-mediated delivery of oligodeoxynucleotides in vivo. Drug Deliv 2002;9(3):169-80
92. Santel A, Aleku M, Keil O, et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther 2006;13(16):1222-34
93. Minakuchi Y, Takeshita F, Kosaka N, et al. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 2004;32(13):E109
94. Julian TM. The efficacy of Marlex mesh in the repair of severe, recurrent vaginal prolapse of the anterior midvaginal wall. Am J Obstet Gynecol 1996;175(6):1472-5
95. http://clinicaltrials.gov/
96. Aigner A. Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo. J Biomed Biotechnol 2006;2006(4):71659
97. Patil SD, Rhodes DG, Burgess DJ. DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J 2005;7(1):E61-E77
98. Heidel JD. Linear cyclodextrin-containing polymers and their use as delivery agents. Expert Opin Drug Deliv 2006;3(5):641-6
99. Bartlett DW, Davis ME. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol Bioeng 2007;97(4):909-21
100. Bartlett DW, Davis ME. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug Chem 2007;18(2):456-68
101. Xu L, Huang CC, Huang W, et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther 2002;1(5):337-46
102. Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005;23(6):709-17
103. Peer D, Zhu P, Carman CV, Lieberman J, Shimaoka M. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc Natl Acad Sci USA 2007;104(10):4095-100
104. Napoli C, Lemieux C, Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 1990;2:279-89
105. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-11
106. Reinhart BJ, Slack FJ, Basson M, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans Nature 2000;403(6772):901-6
107. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000;101(1):25-33
108. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8
109. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001;294:853-8
110. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524-9
111. Jiang M, Milner J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 2002;21:6041-8
112. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene 2007;26:2799-803
113. http://www.wiley.co.uk./genmed/clinical/
114. www.alynylam.com
115. www.cytrx.com